Economics of dry needling and botulinum toxin type A for treatment of post-stroke spasticity: a review

Daniel Fernández , Clara Pujol , Carmen Ruber , Sandra Calvo , Mindy F. Levin , Pablo Herrero , Eva María Gómez-Trullén

Exploration of Neuroprotective Therapy ›› 2022, Vol. 2 ›› Issue (3) : 131 -140.

PDF (1523KB)
Exploration of Neuroprotective Therapy ›› 2022, Vol. 2 ›› Issue (3) :131 -140. DOI: 10.37349/ent.2022.00024
Review
research-article
Economics of dry needling and botulinum toxin type A for treatment of post-stroke spasticity: a review
Author information +
History +
PDF (1523KB)

Abstract

Stroke is one of the most common causes of disability and exerts a high burden of direct and indirect costs. Stroke may cause spasticity, which limits patients’ abilities and affects their activities of daily living, decreasing their quality of life. Conventional treatments are based on physical therapy, anti-spasticity medication, and botulinum toxin type A (BTX-A). However, recently, non-pharmacological approaches have been used, such as dry needling (DN) of myofascial trigger points. BTX-A and DN are two treatments that aim to decrease spasticity in patients with stroke, but their mode of action, application, and costs differ. Thus, there is a need to determine the comparative economics of post-stroke spasticity treatments. For this purpose, a search for all types of cost-effectiveness studies (randomized controlled trials, matched controls, and cohorts) and models of epidemiological data was performed. Studies were selected if they included economic outcomes in stroke patients treated with BTX-A or DN. As a result, 7 studies of BTX-A and 2 of DN were selected. Similarities were found in the outcomes used to assess the effectiveness of both treatments in most studies, with modifications of the Ashworth Scale [Modified Ashworth Scale (MAS)/Modified Modified Ashworth Scale (MMAS)] and quality-adjusted life year (QALY) being the main indicators of effectiveness. However, both the duration of the studies and the evaluation of costs were highly heterogeneous, making comparison difficult. In conclusion, both BTX-A and DN are cost-effective to treat spasticity in patients with stroke, but there is a need for comparative studies to make direct comparisons of cost-effectiveness with the most frequently used outcomes such as the MMAS and QALYs.

Keywords

Stroke / spasticity / dry needling / botulinum toxin / cost-effectiveness

Cite this article

Download citation ▾
Daniel Fernández, Clara Pujol, Carmen Ruber, Sandra Calvo, Mindy F. Levin, Pablo Herrero, Eva María Gómez-Trullén. Economics of dry needling and botulinum toxin type A for treatment of post-stroke spasticity: a review. Exploration of Neuroprotective Therapy, 2022, 2 (3) : 131-140 DOI:10.37349/ent.2022.00024

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Ma VY, Chan L, Carruthers KJ. Incidence, prevalence, costs, and impact on disability of common conditions requiring rehabilitation in the United States: stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, osteoarthritis, rheumatoid arthritis, limb loss, and back pain. Arch Phys Med Rehabil. 2014; 95: 986-95.e1.

[2]

GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021; 20: 795-820.

[3]

Kuriakose D, Xiao Z. Pathophysiology and treatment of stroke: present status and future perspectives. Int J Mol Sci. 2020; 21: 7609.

[4]

Pan F, Hernandez L, Ward A. Cost-effectiveness of stroke treatments and secondary preventions. Expert Opin Pharmacother. 2012; 13: 1751-60.

[5]

Ramos-Lima MJM, Brasileiro IC, de Lima TL, Braga-Neto P. Quality of life after stroke: impact of clinical and sociodemographic factors. Clinics (Sao Paulo). 2018; 73: e418.

[6]

Rochmah TN, Rahmawati IT, Dahlui M, Budiarto W, Bilqis N. Economic burden of stroke disease: a systematic review. Int J Environ Res Public Health. 2021; 18: 7552.

[7]

Godwin KM, Wasserman J, Ostwald SK. Cost associated with stroke: outpatient rehabilitative services and medication. Top Stroke Rehabil. 2011; 18: 676-84.

[8]

Thibaut A, Chatelle C, Ziegler E, Bruno MA, Laureys S, Gosseries O. Spasticity after stroke: physiology, assessment and treatment. Brain Inj. 2013; 27: 1093-105.

[9]

Duncan PW. Stroke disability. Phys Ther. 1994; 74: 399-407.

[10]

Fernández-de-Las-Peñas C, Pérez-Bellmunt A, Llurda-Almuzara L, Plaza-Manzano G, De-la-Llave-Rincón AI, Navarro-Santana MJ. Is dry needling effective for the management of spasticity, pain, and motor function in post-stroke patients? A systematic review and meta-analysis. Pain Med. 2021; 22: 131-41.

[11]

Brandín-de la Cruz N, Calvo S, Rodríguez-Blanco C, Herrero P, Bravo-Esteban E. Effects of dry needling on gait and muscle tone in Parkinson’s disease: a randomized clinical trial. Acupunct Med. 2022; 40: 3-12.

[12]

Del Pilar Pérez-Trujillo M, González-Platas M, Pérez-Martín MY, Revert-Gironés MC, González-Platas J. Dry needling for treating spasticity in multiple sclerosis. J Phys Ther Sci. 2021; 33: 505-10.

[13]

Ozcakir S, Sivrioglu K. Botulinum toxin in poststroke spasticity. Clin Med Res. 2007; 5: 132-8.

[14]

Domingo A, Mayoral O, Monterde S, Santafé MM. Neuromuscular damage and repair after dry needling in mice. Evid Based Complement Alternat Med. 2013; 2013: 260806.

[15]

Travell JG, Simons DG. Myofascial pain and dysfunction: the trigger point manual. 3rd ed. Baltimore: Lippincott Williams & Wilkins; 2018.

[16]

Dong Y, Wu T, Hu X, Wang T. Efficacy and safety of botulinum toxin type A for upper limb spasticity after stroke or traumatic brain injury: a systematic review with meta-analysis and trial sequential analysis. Eur J Phys Rehabil Med. 2017; 53: 256-67.

[17]

Calvo S, Brandín-de la Cruz N, Jiménez-Sánchez C, Bravo-Esteban E, Herrero P. Effects of dry needling on function, hypertonia and quality of life in chronic stroke: a randomized clinical trial. Acupunct Med. 2021;[Epub ahead of print].

[18]

Cuenca Zaldívar JN, Calvo S, Bravo-Esteban E, Oliva Ruiz P, Santi-Cano MJ, Herrero P. Effectiveness of dry needling for upper extremity spasticity, quality of life and function in subacute phase stroke patients. Acupunct Med. 2021; 39: 299-308.

[19]

Kaku M, Simpson DM. Spotlight on botulinum toxin and its potential in the treatment of stroke-related spasticity. Drug Des Devel Ther. 2016; 10: 1085-99.

[20]

Yiannakopoulou E. Serious and long-term adverse events associated with the therapeutic and cosmetic use of botulinum toxin. Pharmacology. 2015; 95: 65-9.

[21]

Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016; 86: 1818-26.

[22]

Fernández Sanchis D, Cuenca Zaldívar JN, Calvo S, Herrero P, Gómez Barrera M. Cost-effectiveness of upper extremity dry needling in the rehabilitation of patients with stroke. Acupunct Med. 2022; 40: 160-8.

[23]

Fernández-Sanchis D, Brandín-de la Cruz N, Jiménez-Sánchez C, Gil-Calvo M, Herrero P, Calvo S. Cost-effectiveness of upper extremity dry needling in chronic stroke. Healthcare (Basel). 2022; 10: 160.

[24]

Ward A, Roberts G, Warner J, Gillard S. Cost-effectiveness of botulinum toxin type A in the treatment of post-stroke spasticity. J Rehabil Med. 2005; 37: 252-7.

[25]

Shaw L, Rodgers H, Price C, van Wijck F, Shackley P, Steen N, et al. BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A. Health Technol Assess. 2010; 14: 1-113, iii-iv.

[26]

Burbaud P, Ducerf C, Cugy E, Dubos JL, Muller F, Guehl D, et al. Botulinum toxin treatment in neurological practice: how much does it really cost? A prospective cost-effectiveness study. J Neurol. 2011; 258: 1670-5.

[27]

Doan QV, Gillard P, Brashear A, Halperin M, Hayward E, Varon S, et al. Cost-effectiveness of onabotulinumtoxinA for the treatment of wrist and hand disability due to upper-limb post-stroke spasticity in Scotland. Eur J Neurol. 2013; 20: 773-80.

[28]

Rychlik R, Kreimendahl F, Schnur N, Lambert-Baumann J, Dressler D. Quality of life and costs of spasticity treatment in German stroke patients. Health Econ Rev. 2016; 6: 27.

[29]

Lazzaro C, Baricich A, Picelli A, Caglioni PM, Ratti M, Santamato A. AbobotulinumtoxinA and rehabilitation vs rehabilitation alone in post-stroke spasticity: a cost-utility analysis. J Rehabil Med. 2020; 52: jrm00016.

[30]

Turcu-Stiolica A, Subtirelu MS, Bumbea AM. Cost-utility analysis of incobotulinumtoxin-A compared with conventional therapy in the management of post-stroke spasticity in Romania. Front Pharmacol. 2020; 10: 1516.

[31]

Abogunrin S, Hortobagyi L, Remak E, Dinet J, Gabriel S, Bakheit AMO. Budget impact analysis of botulinum toxin A therapy for upper limb spasticity in the United Kingdom. Clinicoecon Outcomes Res. 2015; 7: 185-93.

[32]

Makino K, Tilden D, Guarnieri C, Mudge M, Baguley IJ. Cost effectiveness of long-term incobotulinumtoxin-A treatment in the management of post-stroke spasticity of the upper limb from the Australian payer perspective. Pharmacoecon Open. 2019; 3: 93-102.

[33]

Esquenazi A. Improvements in healthcare and cost benefits associated with botulinum toxin treatment of spasticity and muscle overactivity. Eur J Neurol. 2006; 13: 27-34.

[34]

Esquenazi A, Delgado MR, Hauser RA, Picaut P, Foster K, Lysandropoulos A, et al. Duration of symptom relief between injections for abobotulinumtoxinA (Dysport®) in spastic paresis and cervical dystonia: comparison of evidence from clinical studies. Front Neurol. 2020; 11: 576117.

PDF (1523KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉